Literature DB >> 22136887

Nonlinear compartmental model of 18F-choline.

Federico Tavola1, Tilman Janzen, Augusto Giussani, Danya Facchinetti, Ivan Veronese, Helena Uusijärvi-Lizana, Soren Mattsson, Christoph Hoeschen, Marie Claire Cantone.   

Abstract

INTRODUCTION: This work develops a compartmental model of (18)F-choline in order to evaluate its biokinetics and so to describe the temporal variation of the radiopharmaceuticals' uptake in and clearance from organs and tissues.
METHODS: Ten patients were considered in this study. A commercially available tool for compartmental analysis (SAAM II) was used to model the values of activity concentrations in organs and tissues obtained from PET images or from measurements of collected blood and urine samples.
RESULTS: A linear compartmental model of the biokinetics of the radiopharmaceutical was initially developed. It features a central compartment (blood) exchanging with organs. The structure describes explicitly liver, kidneys, spleen, blood and urinary excretion. The linear model tended to overestimate systematically the activity in the liver and in the kidney compartments in the first 20 min post-administration. A nonlinear process of kinetic saturation was considered, according to the typical Michaelis-Menten kinetics. Therefore nonlinear equations were added to describe the flux of (18)F-choline from blood to liver and from blood to kidneys. The nonlinear model showed a tendency for improvement in the description of the activity in liver and kidneys, but not for the urine.
CONCLUSIONS: The simple linear model presented is not able to properly describe the biokinetics of (18)F-choline as measured in prostatic cancer patients. The introduction of nonlinear kinetics, although based on physiologically plausible assumptions, resulted in nonsignificant improvements of the model predictive power.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22136887     DOI: 10.1016/j.nucmedbio.2011.09.002

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  3 in total

1.  Pharmacokinetic Modeling of 18F-FDOPA PET in the Human Brain for Early Parkinson's Disease

Authors:  Wirunpatch Buratachwatanasiri; Maythinee Chantadisai; Jaruwan Onwanna; Yuda Chongpison; Yothin Rakvongthai; Kitiwat Khamwan
Journal:  Mol Imaging Radionucl Ther       Date:  2021-06-03

2.  Quantification of internal dosimetry in PET patients II: Individualized Monte Carlo-based dosimetry for [18F]fluorocholine PET.

Authors:  Sara Neira; Jacobo Guiu-Souto; Paulino Pais; Sofía Rodríguez Martínez de Llano; Carlos Fernández; Virginia Pubul; Álvaro Ruibal; Miguel Pombar; Araceli Gago-Arias; Juan Pardo-Montero
Journal:  Med Phys       Date:  2021-07-29       Impact factor: 4.506

3.  Optimal scan time for evaluation of parathyroid adenoma with [(18)F]-fluorocholine PET/CT.

Authors:  Sebastijan Rep; Luka Lezaic; Tomaz Kocjan; Marija Pfeifer; Mojca Jensterle Sever; Urban Simoncic; Petra Tomse; Marko Hocevar
Journal:  Radiol Oncol       Date:  2015-11-27       Impact factor: 2.991

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.